ArticleBMJ (Clinical research ed.)2024

SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.

Edouard L Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.